MarginsXMarginsX
Home › Markets › Health Care › MAZE

Maze Therapeutics Inc. (MAZE)

MAZE trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$33.90
-1.25% on the day
Market cap
$1.9B
Small cap
Revenue · 2024
$167.5M
No prior year to compare
Net income · 2024
$52.2M
31.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1842295/000119312526122778/0001193125-26-122778-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.

Profile

FieldValue
TickerMAZE on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2025
SEC CIK0001842295
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2024

LineValue
Revenue$167.5M
Net income$52.2M
Operating income$57.6M
Net margin31.2%
Operating margin34.4%
Revenue growthNo prior-year revenue to compare
Cash$196.8M
Total assets$240.5M
P/E (computed)35.5×
P/S (computed)11.1×

Warning signs

Cash runway
16.1 months
$154.2M cash at September 30, 2026
Share count, 1 year
+13.6%
2025-11-03 to 2026-11-04
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$22.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$154.2M cash; operating cash flow -$28.7M a quarter.Report 2026-09-30
Shares outstanding54,683,345 (2026-11-04); 48,119,444 a year earlier.Cover page 2026-11-04
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-04-22
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Mateo, California, United StatesPCAOB Form AP 2026-04-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $22.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$48.0M-$32.8M$154.2M$39.1MNeeds four quarters10-Q 2026-11-09
Q2 2026
2026-06-30
$0-$44.7M-$15.1M$202.6M$39.0MNeeds four quarters10-Q 2026-08-11
Q1 2026
2026-03-31
$20.0M-$24.2M-$39.1M$198.8M$38.8MNeeds four quarters10-Q 2026-05-12
Q4 2025
2025-12-31
Not filed-$34.6M-$27.7M$189.2MNo debt tagsNeeds four quarters10-K 2026-03-25
Q3 2025
2025-09-30
Not filed-$30.1M-$24.6M$316.8MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2025
2025-06-30
$0-$33.7M-$30.1M$264.5MNo debt tagsNeeds four quarters10-Q 2025-08-12
Q1 2025
2025-03-31
Not filed-$32.8M-$29.5M$294.4MNo debt tagsNeeds four quarters10-Q 2026-08-11
Q4 2024
2024-12-31
$0-$29.6M-$22.5M$196.8MNo debt tags$167.5M10-K 2026-03-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentPOS AM2026-05-12
Latest annual report10-K2026-03-25
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 225 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.4%
1 month+28.8%
3 months+24.1%
Year to date-17.1%
1 year+7.8%
From 52-week high-33.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
COAGHemab Therapeutics Holdings Inc.$39.05-4.42%$1.8B
RXRXRecursion Pharmaceuticals Inc.$2.90-8.79%$1.8B
BCRXBioCryst Pharmaceuticals Inc.$7.45-2.10%$1.9B
WWBWindward Bio Group AG Common Shares$30.04+5.40%$1.7B
ALVOAlvotech$4.41+5.13%$1.7B
REPLReplimune Group Inc.$21.41-2.19%$2.0B
VIRVir Biotechnology Inc.$9.58-3.82%$1.6B
MESOMesoblast Limited$12.45-6.18%$1.6B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier